Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16319475 | 0.88 | SCN9A (0.62) | SCN9ASLC6A4HTR2AKCNH2SCN5A | |
| SCHEMBL16319613 | 0.86 | SCN9A (0.60) | SCN9ASLC6A4HTR2AKCNH2 | |
| SCHEMBL680427 | 0.85 | SCN9A (0.59) | SCN9ASCN5A | |
| SCHEMBL16319310 | 0.85 | SCN9A (0.71) | SCN9ASCN5A | |
| SCHEMBL680556 | 0.82 | SCN9A (0.68) | SCN9ASCN5A | |
| SCHEMBL16319531 | 0.82 | SCN9A (0.58) | SCN9ASCN5A | |
| SCHEMBL16319332 | 0.82 | SCN9A (0.61) | SCN9ASLC6A4HTR2AKCNH2SCN5A | |
| SCHEMBL364837 | 0.81 | SLC6A4 (0.60) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL10250680 | 0.81 | SLC6A4 (0.55) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL22559366 | 0.79 | SCN9A (0.54) | SCN9ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | claimed |
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| EP-2593427-A1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007883-A1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | SCN9A 13/4885SLC6A4 597/4885HTR2A 1805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.